Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2021-004167-27-NL
EUCTR2021-004167-27-NLActive, not recruitingPhase 1

A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity

Rhythm Pharmaceuticals Limited0 sites10 target enrollmentStarted: October 5, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
10
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Patients must have obesity due to either:
  • •a. POMC, PCSK1, or LEPR deficiency, confirmed by genetic testing demonstrating biallelic variants that are interpreted as pathogenic, likely pathogenic, or of undetermined significance (VUS) by the American College of Medical Genetics and Genomics (ACMG) criteria, or
  • •b. BBS as defined by both (1) the Beales Criteria, 1999 (Beales 1999 [Appendix 16.1]) AND (2) genetic confirmation of homozygous or compound heterozygous loss-of-function mutation in BBS genes.
  • •2. Age between 2 to <6 years at the time of informed consent are eligible for the study.
  • •3. Obese, defined as body mass index (BMI) =97th percentile for age and gender AND body weight of at least 20 kg at the time of enrollment
  • •4. Parent or guardian of study participant is able to communicate well with the PI, to understand and comply with the requirements of the study (including once daily (QD) injection regimen and all other study procedures) and is able to understand and sign the written consent.
  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range: 10
  • •F.1.2 Adults (18-64 years) no
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. HbA1c >9.0% at screening
  • •2. History of significant liver disease other than non-alcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
  • •3. Glomerular filtration rate (GFR) <60 mL/min
  • •4. History or close family history (parents or siblings) of melanoma, or patient history of oculocutaneous albinism.
  • •5. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion), determined as part of a comprehensive skin evaluation performed by the PI during screening. Any concerning lesions identified during screening will be biopsied and results known to be benign prior to enrollment.
  • •6. Patient is, in the opinion of the Study PI, not suitable to participate in the study.
  • •7. Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing.
  • •8. Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.
  • •9. Significant hypersensitivity to any excipient in the study drug.
  • •10. Inadequate hepatic function as evidenced by elevated Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) values >5x Upper limit of normal (ULN).

Investigators

Similar Trials

Active, not recruiting
Phase 1
A study to investigate treatment of Setmelanotide in children from 2 to 6 years old that have a form of genetic obesityPOMC deficiency obesity due to mutations in the POMC genePCSK1 deficiency obesity due to mutations in the PCSK1 geneLEPR deficiency obesity due to mutations in the LEPR geneBardet-Biedl syndromeMedDRA version: 23.0Level: PTClassification code 10084105Term: Leptin receptor deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 23.0Level: PTClassification code 10083937Term: Pro-opiomelanocortin deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10048680Term: Bardet-Biedl syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2021-004167-27-ESRhythm Pharmaceuticals Limited10
Active, not recruiting
Phase 1
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)MedDRA version: 16.0Level: PTClassification code 10059176Term: Juvenile idiopathic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2012-003195-39-ESBristol-Myers Squibb International Corporation210
Active, not recruiting
Phase 1
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
EUCTR2012-003195-39-BEBristol-Myers Squibb International Corporation234
Active, not recruiting
Phase 1
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
EUCTR2012-003195-39-FRBristol-Myers Squibb International Corporation210
Active, not recruiting
Phase 1
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to biologic or non biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
EUCTR2012-003195-39-DEBristol-Myers Squibb International Corporation234